146 related articles for article (PubMed ID: 16903979)
1. Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy.
Coll B; Alonso-Villaverde C; Parra S; Rabassa A; Martorell L; Joven J; Masana L
HIV Med; 2006 Sep; 7(6):356-60. PubMed ID: 16903979
[TBL] [Abstract][Full Text] [Related]
2. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.
Bogner JR; Lutz B; Klein HG; Pollerer C; Troendle U; Goebel FD
HIV Med; 2004 Jul; 5(4):264-72. PubMed ID: 15236615
[TBL] [Abstract][Full Text] [Related]
3. CCR2-64I and CXCL12 3'A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy.
Passam AM; Zafiropoulos A; Miyakis S; Zagoreos I; Stavrianeas NG; Krambovitis E; Spandidos DA
J Clin Virol; 2005 Dec; 34(4):302-9. PubMed ID: 16286054
[TBL] [Abstract][Full Text] [Related]
4. [Distribution of HIV resistance CCR5-delta 32, CCR2-64 I and SDF1-3'A alleles and their polymorphisms in the Han population in China].
Wang F; Jin L; Lei Z; Shi H; Hong W; Xu D; Shi M; Jiang J; Wang Y; Zhang B; Liu M; Li Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Aug; 21(4):256-60. PubMed ID: 11860793
[TBL] [Abstract][Full Text] [Related]
5. Distribution of CCR5delta32, CCR2-64I and SDF1-3'A and plasma levels of SDF-1 in HIV-1 seronegative North Indians.
Verma R; Gupta RB; Singh K; Bhasin R; Anand Shukla A; Chauhan SS; Luthra K
J Clin Virol; 2007 Mar; 38(3):198-203. PubMed ID: 17240189
[TBL] [Abstract][Full Text] [Related]
6. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
7. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
Nahon P; Sutton A; Rufat P; Faisant C; Simon C; Barget N; Trinchet JC; Beaugrand M; Gattegno L; Charnaux N
Eur J Gastroenterol Hepatol; 2007 May; 19(5):425-31. PubMed ID: 17413295
[TBL] [Abstract][Full Text] [Related]
8. Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression.
Daar ES; Lynn HS; Donfield SM; Lail A; O'Brien SJ; Huang W; Winkler CA;
J Infect Dis; 2005 Nov; 192(9):1597-605. PubMed ID: 16206074
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
10. [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
Wasik TJ; Smoleń J; Kruszyński P; Bratosiewicz-Wasik J; Beniowski M
Wiad Lek; 2005; 58(9-10):500-7. PubMed ID: 16529059
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
12. [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?].
Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
Dtsch Med Wochenschr; 2002 Sep; 127(36):1807-12. PubMed ID: 12215924
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
14. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
15. Distribution of two HIV-1-resistant polymorphisms (SDF1-3'A and CCR2-64I alleles) in the Polish population.
Lewandowska M; Franciszkiewicz K; Prokop J; Ofori H; Jagodzinski PP
J Hum Genet; 2002; 47(11):585-9. PubMed ID: 12436194
[TBL] [Abstract][Full Text] [Related]
16. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
[TBL] [Abstract][Full Text] [Related]
17. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.
Lambert JS; Machado ES; Watson DC; Sill AM; Lim JK; Charurat M; Cunha SM; Afonso AO; Oliviera RH; Tanuri A; DeVico AL
Pediatr Infect Dis J; 2007 Oct; 26(10):935-44. PubMed ID: 17901800
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
19. Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HIV-1) and patients infected with HIV-1 from the Brazilian population.
Reiche EM; Watanabe MA; Bonametti AM; Morimoto HK; Morimoto AA; Wiechmann SL; Matsuo T; Miranda HC; Reiche FV; Oliveira KB
Int J Immunogenet; 2006 Apr; 33(2):127-33. PubMed ID: 16611258
[TBL] [Abstract][Full Text] [Related]
20. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
